This section has been revised in the light of the recent NICE guidelines. Following this publication we have removed specific drug protocols as it is clear that medication should only be prescribed by Psychiatrists. For further information about treatment of depression please refer to NICE clinical guidance – Depression in children and young people (CG28).
Drug treatment is not recommended for mild depression in children.
Children with moderate/severe depression should be offered a specific psychological therapy (e.g. Cognitive Behavioural Therapy) as first line.
If depression is not responsive to psychological therapy, young people (12-18 years) may be offered fluoxetine. Fluoxetine may be cautiously considered for 5-11 year olds but there is less evidence to support its use.
Antidepressants must only be prescribed following assessment and diagnosis by a child and adolescent psychiatrist and in combination with a psychological therapy.
Professionals must monitor response to antidepressants and be vigilant for adverse drug effects.
General measures
Consider any underlying disability and the impact this has on sleep patterns – e.g visual impairment, autism, seizures.
Tablet (modified release): 2mg
Capsule (immediate release): 1mg, 2mg, 2.5mg, 3mg, 5mg and 10mg named patient from ‘specials’ manufacturers
1 month-18 years: initial dose 2–3mg, increasing every 1–2 weeks dependent on effectiveness up to maximum 12mg daily.
Use for Sleep disturbance due to disruption of circadian rhythm (not anxiolytic). Can combine instant release and modified release formulations to tailor to need.
Licence: Unlicensed. for children. M/R tablets (Circadin®) licensed for use in elderly. Instant release available on named patient basis.
Tablet: chloral betaine 707mg = choral hydrate 414mg - Welldorm®10mg, Oral solution: 500mg in 5mL, 200mg in 5mL (both from ‘specials’ manufacturers)
Suppositories : 25mg, 50mg, 60mg, 100mg, 200mg, 500mg from ‘specials’ manufacturers).
Neonate: initial dose of 30mg/kg as a single dose at night. May be increased to 45mg/kg at night or when required,
1 month–12 years: initial dose of 30mg/kg as a single dose at night. May be increased to 50mg/kg at night or when required. Maximum single dose 1g,
12–18 years: initial dose of 500 mg as a single dose at night or when required. Dose may be increased if necessary to 1-2 g. Maximum single dose 2 g.
Contraindications and warnings: Accumulates on prolonged use and should be avoided in severe renal or hepatic impairment.
Licence: Licensed for use in children >2yr.
Tablet: 10mg, 25mg
Elixir: 5mg in 5mL
Injection: 25mg in 1mL as 1 mL ampoule.
2-5yr: 15-20mg nocte
5-10yr: 20-25mg nocte
10-18yr: 25-50mg nocte
Contraindications and warnings: Porphyria; CNS depression; hypersensitivity to phenothiazines. Do not use with, or within 2 weeks of taking MAOIs. Advised for short term use only.
Licence: Licensed for use in children >2yr.
Tablet: 10mg, 20mg.
Capsules: 10mg, 15mg, 20mg, 30mg. Oral solution: 10mg in 5mL.
Adult: 10–20mg at night. Dose may be increased to 40mg at night in exceptional circumstances
Contraindications and warnings: caution in severe liver disease. Avoid in CNS depression and acute pulmonary insufficiency. Interactions: see appropriate text.
Licence: not licensed for use in children.
PCM © 2012